Edition:
India

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

39.70CHF
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
CHF39.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
82,601
52-wk High
CHF82.00
52-wk Low
CHF25.10

Latest Key Developments (Source: Significant Developments)

Santhera successfully places 60 mln Swiss francs senior convertible bonds
Friday, 10 Feb 2017 

Santhera Pharmaceuticals Holding AG :Santhera successfully places 60 million Swiss francs ($59.67 million) senior convertible bonds.  Full Article

Santhera launches senior convertible bond issue
Friday, 10 Feb 2017 

Santhera Pharmaceuticals Holding AG : Santhera launches senior convertible bond issue . To launch of an offering of 50 million Swiss francs ($49.89 million) senior unsecured convertible bondsdue 2022 with possibility of an increase by a maximum of 10 million francs to 60 million francs .Convertible bonds have a 5-year maturity, are expected to carry a coupon of between 4.5 percent and 5.0 percent per annum.  Full Article

Santhera announces appointment of Kristina Timdahl as Chief Medical Officer
Tuesday, 4 Oct 2016 

Santhera Pharmaceuticals Holding AG : Santhera announces appointment of Kristina Timdahl as Chief Medical Officer and head of development as of January 2017 .Will replace Nick Coppard, who will retire in January 2017.  Full Article

Santhera Pharmaceuticals Holding H1 net loss widens to CHF 18 million
Tuesday, 6 Sep 2016 

Santhera Pharmaceuticals Holding AG : As of June 30, 2016, Santhera had cash and cash equivalents of 63.6 million Swiss francs ($64.89 million) (December 31, 2015: 76.9 million francs) . H1 operating loss amounted to 17.2 million francs (H1 2015: -6.2 million francs) leading to a net result of -18.0 million francs (H1 2015: -6.4 million francs) .Expects net sales of Raxone in 2016 to reach 16 to 18 million francs.  Full Article

Santhera Pharmaceuticals Holding updates on U.S. regulatory filing for Raxone
Thursday, 14 Jul 2016 

Santhera Pharmaceuticals Holding AG : Announces that it has received written correspondence from U.S. Food and Drug Administration (FDA) on its proposed subpart H approval pathway for Raxone in DMD patients not taking concomitant glucocorticoids .FDA concluded that results from SIDEROS trial, should be provided at time of filing to support an NDA for treatment of DMD patients irrespective of their glucocorticoid use status.  Full Article

Santhera reports new data with Raxone in DMD patients
Wednesday, 1 Jun 2016 

Santhera Pharmaceuticals Holding AG : New data from Santhera's phase III trial (DELOS) in Duchenne muscular dystrophy (DMD) in Neuromuscular Disorders .These data show that DMD patients treated with Raxone have reduced risk of bronchopulmonary complications.  Full Article

Santhera files marketing authorization application in European Union for Raxone
Tuesday, 31 May 2016 

Santhera Pharmaceuticals Holding AG : Santhera files marketing authorization application in the European Union for Raxone for the treatment of Duchenne muscular dystrophy .New indication was submitted as type II variation of company's existing marketing authorization for raxone granted last year. Raxone has orphan drug designation for DMD in EU.  Full Article

Santhera receives FDA fast track designation for Omigapil
Friday, 20 May 2016 

Santhera Pharmaceuticals Holding AG :Santhera receives FDA fast track designation for Omigapil for the treatment of congenital muscular dystrophies (CMD).  Full Article

Santhera Pharmaceuticals Holding submits briefing material and meeting request to FDA to discuss filing of a new drug application for Raxone
Tuesday, 3 May 2016 

Santhera Pharmaceuticals Holding AG:Says submitted comprehensive briefing material and a meeting request to fda to discuss filing of a new drug application for raxone (idebenone) for treatment of dmd patients not taking concomitant glucocorticoids.  Full Article

BRIEF-Santhera: negative opinion from the CHMP for Raxone in DMD

* SANTHERA RECEIVES NEGATIVE OPINION FROM THE CHMP FOR ITS MARKETING AUTHORIZATION APPLICATION FOR RAXONE® IN DMD AND INTENDS TO APPEAL THIS OPINION